drugset / Trial / NCT03640949

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

NCT03640949

Phase 2/3 Completed 501 enrolled Lars Wiuff Andersen University of Aarhus · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of vasopressin and methylprednisolone during adult in-hospital cardiac arrest. There will be ten enrolling sites in Denmark. 492 adult patients with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.

Timeline

Start
2018-09-17
Primary completion
2021-01-21
Completion
2022-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 40 mg
Subject Vasopressin Peptide 20 iu

Indications